- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03414034
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males ≥ 18 years of age on the day of consenting to the study.
- Ability to swallow the study drug as a whole tablet.
- Histologically confirmed prostate adenocarcinoma without significant small- cell/neuroendocrine or other variant histologies, with rising PSA and/or radiographic progression in the setting of castration-level testosterone (< 50 ng/dL) indicating mCRPC. Participants must have either undergone surgical castration or continue on GnRH agonist/antagonist on the appropriate schedule throughout the study period.
- Asymptomatic or minimally symptomatic disease.
- Metastatic disease by bone scan or other nodal or visceral lesions on CT or MRI at any time (past or present).
- Participant currently receiving abiraterone and prednisone for CRPC.
Participant has been on abiraterone for castration-sensitive prostate cancer (CSPC) or castration-resistant prostate cancer (CRPC). Participants who have received abiraterone for CSPC must have had a response to hormonal therapy, as defined by any decline in PSA, radiographic response and/or clinical benefit after starting hormonal therapy.
Participants who have received abiraterone for CRPC must have responded to abiraterone, defined by any decline in PSA, radiographic response, and/or clinical benefit after starting abiraterone.
- Two rising PSA values separated by at least 1 week, one showing a rise of at least 0.3 ng/mL and one confirmatory value not showing a decline, while on abiraterone therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
Participant has adequate bone marrow and organ function as shown by:
- Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
- Platelets ≥ 100 x 10^9/L
- Hemoglobin (Hgb) ≥ 9.0 g/dL
- Serum creatinine ≤ 2 x the upper limit of normal (ULN)
- Total serum bilirubin ≤ 1.5 x ULN (in participants with known Gilbert Syndrome, a total bilirubin ≤ 3.0 x ULN, with direct bilirubin ≤ 1.5 x ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN (or ≤ 5.0 x ULN if hepatic metastases are present)
Exclusion Criteria:
- Major surgery within 28 days prior to starting study drug or has not recovered from major side effects of the surgery.
- Rapidly progressive symptoms of mCRPC.
- Acute neurological dysfunction as a result of bone metastasis.
- Previously treated with enzalutamide or experimental therapies directed against androgen receptor (ie, apalutamide).
Use of any chemotherapy, investigational agents, immunotherapy, or hormonal therapy other than GnRH agonists within 28 days of the start of treatment on protocol.
Use of bone targeted agents including bisphosphonates and RANK ligand inhibitors is allowed if on stable dose; Xgeva or Zometa cannot be started within 28 days of initiating study therapy.
- Systemic corticosteroids except as part of on label treatment prostate cancer regimens. Note: Topical applications (eg, rash), inhaled sprays (eg, obstructive airways diseases), eye drops or local injections (eg, intra-articular) are allowed.
- Treatment with any of the drugs listed in Section 8.4.5 at the time of study treatment initiation.
- Has received wide field radiotherapy (including therapeutic radioisotopes such as radium 223) ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to starting study drug or has not recovered from side effects of such therapy.
- New York Heart Association (NYHA) Class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition, or hypertensive or metabolic condition.
- Myocardial infarction in the previous 12 weeks (from the start of treatment)
- QT interval with Fridericia's correction [QTcF] >470 milliseconds. The QTcF should be calculated as the arithmetic mean of the QTcF on triplicate ECGs. In the case of potentially correctible causes of QT prolongation (e.g., medications, hypokalemia), the triplicate ECG may be repeated once during screening and that result may be used to determine eligibility.
- Planned concomitant use of medications known to prolong the QT/QTc interval
- Presence of risk factors for torsade de pointes, including family history of Long QT Syndrome or uncorrected hypokalemia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: onvansertib + abiraterone and prednisone
On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 21-day cycle.
Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
This arm was discontinued.
|
Onvansertib orally
Other Names:
Abiraterone orally
Prednisone orally
|
Experimental: Arm B: onvansertib + abiraterone and prednisone
On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 14-day cycle.
Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
|
Onvansertib orally
Other Names:
Abiraterone orally
Prednisone orally
|
Experimental: Arm C: onvansertib + abiraterone and prednisone
On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 12 mg/m^2 for 14 days (Day 1 through Day 14) out of a 21-day cycle.
Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
|
Onvansertib orally
Other Names:
Abiraterone orally
Prednisone orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants With Lack of Prostate-specific Antigen (PSA) Progression per Prostate Cancer Working Group 3 (PCWG3) Criteria After 12 Weeks
Time Frame: Week 12
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change from Baseline in PSA at 12 Weeks
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
|
Maximal Percentage Change from Baseline in PSA
Time Frame: Baseline up to 20 months
|
Baseline up to 20 months
|
|
Absolute Change from Baseline in PSA Response
Time Frame: Baseline up to 20 months
|
Baseline up to 20 months
|
|
Time to PSA Progression per PCWG3 criteria
Time Frame: Baseline up to 20 months
|
Baseline up to 20 months
|
|
Time to Radiographic Progression per PCWG3 criteria
Time Frame: Baseline up to 20 months
|
Baseline up to 20 months
|
|
Radiographic Response per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Time Frame: Baseline up to 20 months
|
Baseline up to 20 months
|
|
Percentage of Participants Who are Adherent to Study Treatment (Per-Protocol Analysis) With Lack of Prostate-specific Antigen (PSA) Progression per Prostate Cancer Working Group 3 (PCWG3) Criteria After 12 Weeks
Time Frame: Week 12
|
Week 12
|
|
Number of Participants With Adverse Events per Common Terminology Criteria for Adverse Events (CTCAE)
Time Frame: Baseline up to 30 days after last dose of study drug (Up to 20 months)
|
Baseline up to 30 days after last dose of study drug (Up to 20 months)
|
|
Number of Participants With Dose Limiting Toxicity (DLT)
Time Frame: Up to 20 months
|
DLT is defined as a hematologic adverse event (AE) of Grade ≥ 3 or nonhematologic AE of Grade ≥ 3 considered related to the study drug(s).
|
Up to 20 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Prednisone
- Onvansertib
Other Study ID Numbers
- TROV-053
- U1111-1208-1579 (Registry Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Castration-Resistant Prostate Cancer
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
Rohan GarjeJanssen Scientific Affairs, LLCNot yet recruitingCastration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
BAMF HealthRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Clarus TherapeuticsRecruitingProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Massachusetts General HospitalBayerCompletedProstate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to BoneUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Hinova Pharmaceuticals Inc.CompletedMetastatic Castration Resistant Prostate CancerChina
Clinical Trials on Onvansertib
-
Taofeek OwonikokoNational Cancer Institute (NCI); Cardiff OncologyNot yet recruitingSmall Cell Lung Carcinoma | Small-cell Lung CancerUnited States
-
Radboud University Medical CenterDutch Cancer SocietyUnknownNeoplasms | Carcinoma | Colorectal Cancer | Gastrointestinal Cancer | Peritoneal CarcinomatosisNetherlands
-
Cardiff OncologyActive, not recruitingMetastatic Colorectal Cancer | Colorectal CancerUnited States
-
Antonio Giordano, MDCardiff OncologyRecruitingBreast Cancer | Metastatic Breast Cancer | Inflammatory Breast Cancer | Invasive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Hormone Receptor Negative Breast Carcinoma | Hormone Receptor/Growth Factor...United States
-
Cardiff OncologyNo longer availableMetastatic Colorectal Cancer | KRAS Gene Mutation
-
Cardiff OncologyCompletedAcute Myeloid LeukemiaUnited States
-
Cardiff OncologyPfizerRecruitingMetastatic Colorectal Cancer | CRC | KRAS/NRAS MutationUnited States
-
Cardiff OncologyCompletedMetastatic Colorectal Cancer | KRAS Gene MutationUnited States
-
Cardiff OncologyActive, not recruitingPancreatic Ductal AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; American Association for... and other collaboratorsRecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal AdenocarcinomaUnited States